Finding That Immune Cells Interact Could Lead to Myeloma Therapies, Study Suggests
One kind of immune cell helps another stay active for years against invaders, a finding that could lead to therapies for autoimmune diseases and certain…
Inês Martins, PhD, managing science editor — 
Articles by Inês Martins
FDA OKs Revlimid as Maintenance Therapy in Multiple Myeloma Auto-HSCT Patients
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple myeloma patients who received an…
Myeloma Patients Treated at High-volume Facilities Have Lower Risk of Death, Study Finds
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…
First Myeloma Patient Joins Trial of Therapy for Cancers That Failed to Respond to Treatment
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.
Artist Will Donate Part of Proceeds from Hollyweed T-shirt Sales to Myeloma
A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization of recreational marijuana — and…
Patients with Indolent Myeloma Don’t Benefit from ICAM1 Inhibitor, Trial Results Show
Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
Phase 1 Trial to Assess Safety of Radioactive Anti-CD33 Antibody in Advanced Myeloma
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
Patients Value Obamacare More Than General Public and Oppose Its Repeal, Survey Says
People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey by PatientsLikeMe has found. They are also…
Revlimid for Myeloma After Stem Cell Transplant Gets Nod from EMA Panel
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Cellectar’s Patent for Anti-cancer Compounds Includes Potential Myeloma Therapy
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…